Quarterly report pursuant to Section 13 or 15(d)

Significant Transactions (Narrative) (Details)

v3.23.3
Significant Transactions (Narrative) (Details)
3 Months Ended 12 Months Ended
Sep. 19, 2022
USD ($)
shares
Sep. 16, 2022
USD ($)
shares
Nov. 01, 2021
USD ($)
lease
$ / shares
shares
Aug. 23, 2021
USD ($)
shares
Sep. 30, 2023
USD ($)
item
Dec. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
General and administrative expenses         $ 3,547,000   $ 5,088,000    
Value of common stock issued         28,000       $ 20,000
Accrued expenses - noncurrent         263,000       527,000
Purchase price allocated       $ 7,500,000          
Series A-2 Preferred Stock [Member]                  
Purchase price allocated       $ 1,760,000          
Secured Term Loan                  
Secured term loan     $ 22,375,000   12,655,000       13,057,000
Interest rate (as percent)     3.25%            
Cost incurred to attain debt         $ 30,000       $ 120,000
RubrYc Therapeutics Inc [Member]                  
Total purchase price   $ 1,000,000              
Fair market value of property   650,000,000              
Amount advanced   484,000,000              
Transaction costs   208,000,000              
Finance leases   $ 814,000 $ 814,000            
Stock purchase agreement, number of shares purchased | shares   102,354              
Liability for the assumed acquisition   $ 5,000,000              
Impairment of current prepaid expense               $ 288,000  
Impairment of non-current prepaid expense               864,000  
Number of shares issued | shares 102,354                
Number of equipment leases | lease     3            
Purchase price allocated $ 1,342,000                
College Station Investors LLC And Bryan Capital [Member]                  
Total purchase price     $ 28,750,000            
Cash payment     28,000,000            
Fair market value of property     $ 151,450            
Percentage of base rent     6.50%            
Cash consideration for equity interest acquired     $ 50,000            
Number of warrants issued | shares     51,583            
Warrants, exercise price per share | $ / shares     $ 33.25            
Shares issued under the Warrant | shares     11,583            
Fair value of the warrant     $ 217,255            
College Station Investors LLC And Bryan Capital [Member] | Secured Term Loan                  
Secured term loan     $ 22,375,000            
College Station Investors LLC And Bryan Capital [Member] | IBio CMO Preferred Tracking Stock                  
Warrants issuable | shares     1            
Percentage of equity interest     0.01%            
Separation Agreement and General Release [Member]                  
General and administrative expenses           $ 2,130,000      
Period of bi-monthly installments of current base salary         24 months        
Period of bi-monthly installments of target bonus         24 months        
Maximum period for coverage of health insurance         18 months        
COBRA subsidy period         18 months        
Number of times on which lump sum cash payment tis o be made | item         6        
Accrued expenses         $ 1,200,000        
Accrued expenses - noncurrent         $ 263,000        
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Therapeutics Inc [Member]                  
Collaboration and license agreement, agreement term       5 years          
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | No Biosimilar Product has been Approved [Member] | RubrYc Therapeutics Inc [Member]                  
Collaboration and license agreement, royalty payment term       10 years          
Series A-2 Preferred Stock [Member]                  
Purchase price allocated               $ 1,760,000  
Series A-2 Preferred Stock [Member] | Stock Purchase Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Therapeutics Inc [Member]                  
Stock purchase agreement, number of shares purchased | shares       2,864,345          
Stock purchase agreement, value of shares purchased       $ 7,500,000